Eidos Therapeutics Inc (EIDX) Stock Price, Quote, News and Overview
NASDAQ:EIDX - Nasdaq -
EIDX Quote, Performance and Key Statistics
122.21
-6.23 (-4.85%)
The current stock price of EIDX is 122.21 null. In the past month the price decreased by -4.04%. In the past year, price increased by 129.37%.
About EIDX
Company Profile
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.
Company Info
Eidos Therapeutics Inc
101 MONTGOMERY STREET SUITE 2550
SAN FRANCISCO CA 94104
CEO: Neil Kumar
Phone: 415-887-1471
Eidos Therapeutics Inc / EIDX FAQ
What is the stock price of Eidos Therapeutics Inc today?
The current stock price of EIDX is 122.21 null. The price decreased by -4.85% in the last trading session.
What is the ticker symbol for Eidos Therapeutics Inc stock?
The exchange symbol of Eidos Therapeutics Inc is EIDX and it is listed on the Nasdaq exchange.
On which exchange is EIDX stock listed?
EIDX stock is listed on the Nasdaq exchange.
What is Eidos Therapeutics Inc worth?
Eidos Therapeutics Inc (EIDX) has a market capitalization of 4.75B null. This makes EIDX a Mid Cap stock.
What are the support and resistance levels for Eidos Therapeutics Inc (EIDX) stock?
Eidos Therapeutics Inc (EIDX) has a support level at 117.32 and a resistance level at 131.59. Check the full technical report for a detailed analysis of EIDX support and resistance levels.
Should I buy Eidos Therapeutics Inc (EIDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EIDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EIDX, evaluating the profitability, health, valuation and growth aspects
- Eidos Therapeutics Inc (EIDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Eidos Therapeutics Inc (EIDX) Sales and EPS estimates to see what analysts future expectations are.
- Eidos Therapeutics Inc (EIDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Eidos Therapeutics Inc (EIDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Eidos Therapeutics Inc (EIDX) Stock Chart to make your own analysis
- Eidos Therapeutics Inc (EIDX) Latest news and press-releases to stay up to date.
Does Eidos Therapeutics Inc (EIDX) stock pay dividends?
EIDX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Eidos Therapeutics Inc (EIDX)?
Eidos Therapeutics Inc (EIDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.65).
EIDX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EIDX. When comparing the yearly performance of all stocks, EIDX is one of the better performing stocks in the market, outperforming 91.31% of all stocks.
EIDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIDX. No worries on liquidiy or solvency for EIDX as it has an excellent financial health rating, but there are worries on the profitability.
EIDX Financial Highlights
Over the last trailing twelve months EIDX reported a non-GAAP Earnings per Share(EPS) of -2.6500000000000004. The EPS decreased by -231.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -79392.91% | ||
| ROA | -62.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
EIDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 55% to EIDX. The Buy consensus is the average rating of analysts ratings from 8 analysts.